CytomX Therapeutics (CTMX) news

Regeneron exec says co eligible to receive $1 bln in potential milestone payment with the start of the first late-stage trial as part of the deal -Conf call

Regeneron Pharmaceuticals, Inc. (REGN) is positioned to receive up to $1 billion in potential milestone payments as part of its expanded collaboration with Sanofi, according to remarks made during a conference call. The companies announced the expansion of their longstanding antibody collaboration,…

Cytomx TherA gets FDA fast track designation for Varseta-M

CytomX Therapeutics has announced plans for an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational therapy Varsetatug masetecan (Varseta-M) for the treatment of late-line metastatic colorectal cancer (mCRC). The company aims to align with the FDA on the…

CytomX Therapeutics Q2 EPS USD -0.09

CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported a net loss per share of -$0.09 for the second quarter of 2026, reflecting continued investment in its clinical-stage pipeline of PROBODY® therapeutics. The company’s Q2 2026 financial results showed a net loss of $18.2 million, or -$0.10 per share…

Cytomx 2Q revenue $1.42M, estimate $6.93M

CytomX Therapeutics (NASDAQ: CTMX) reported second-quarter 2026 revenue of $1.42 million, significantly below the estimated $6.93 million . The company’s earnings per share (EPS) for the quarter was -$0.10, surpassing the consensus estimate of -$0.14 by $0.04. This performance reflects a continued…

CytomX Therapeutics announces appointment of Charles Fuchs, M.D., M.P.H., to the board of directors